RT @OncoAlert: Day1⃣ #GU21 #OncoAlertTopTweet 🚨by @VivekSubbiah Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Partici…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
See our #ASCOGU page for #BladderCancer updates! 👉https://t.co/VCR0x3rgeE👈 #GU21 @ASCO @OncoAlert @ASTRO_org #UroSoMe #UroOnc #OncoAlert #Oncology #PCSM #BlcSM #kcsm #TSCsm #SurgOnc #CTSM #TrialUpdate #ClinOnc #MedOnc
RT @VivekSubbiah: 5/6 Among patients with urothelial carcinoma histology, those harboring a TP53 alteration had a shorter mPFS vs those who…
RT @VivekSubbiah: 4/6 TP53, ERBB2, PI3KCA, FGFR3, and ARID1A alterations were detected in 66%, 29%, 27%, 24%, and 22% of all patients, resp…
RT @OncoAlert: Day1⃣ #GU21 #OncoAlertTopTweet 🚨by @VivekSubbiah Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Partici…
RT @montypal: OMG @neerajaiims @TiansterZhang @DrChoueiri - we have finally succeeded in our mission to turn @VivekSubbiah into a GU medica…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @montypal: OMG @neerajaiims @TiansterZhang @DrChoueiri - we have finally succeeded in our mission to turn @VivekSubbiah into a GU medica…
RT @OncoAlert: Day1⃣ #GU21 #OncoAlertTopTweet 🚨by @VivekSubbiah Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Partici…
Day1⃣ #GU21 #OncoAlertTopTweet 🚨by @VivekSubbiah Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published as Rapid impact paper @oalhalabimd et al
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @montypal: OMG @neerajaiims @TiansterZhang @DrChoueiri - we have finally succeeded in our mission to turn @VivekSubbiah into a GU medica…
OMG @neerajaiims @TiansterZhang @DrChoueiri - we have finally succeeded in our mission to turn @VivekSubbiah into a GU medical oncologist! Welcome to the club, buddy! (And very nice work here w @oalhalabimd @OncHahn @PavlosMsaouel coinciding w @ASCO #GU21)
RT @VivekSubbiah: 🚨🥁 Just in time for #GU21 @ASCO 👉 Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts…
RT @VivekSubbiah: 6/6 Implications: Patients with platinum-refractory mBC derive clinical benefit from participating in early-phase clinica…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 🚨🥁 Just in time for #GU21 @ASCO 👉 Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts…
RT @oalhalabimd: 1/🌟 Excited to share our brief paper with @OncHahn @PavlosMsaouel @JasonRoszik and @MDAndersonNews team, looking at patien…
RT @VivekSubbiah: 🚨🥁 Just in time for #GU21 @ASCO 👉 Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 🚨🥁 Just in time for #GU21 @ASCO 👉 Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts…
RT @VivekSubbiah: 4/6 TP53, ERBB2, PI3KCA, FGFR3, and ARID1A alterations were detected in 66%, 29%, 27%, 24%, and 22% of all patients, resp…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 6/6 Implications: Patients with platinum-refractory mBC derive clinical benefit from participating in early-phase clinica…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 3/6 Patients' tumors or circulating tumor DNA were analyzed by NGS. The median progression-free survival was 4.2 months,…
RT @VivekSubbiah: 5/6 Among patients with urothelial carcinoma histology, those harboring a TP53 alteration had a shorter mPFS vs those who…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 4/6 TP53, ERBB2, PI3KCA, FGFR3, and ARID1A alterations were detected in 66%, 29%, 27%, 24%, and 22% of all patients, resp…
RT @VivekSubbiah: 4/6 TP53, ERBB2, PI3KCA, FGFR3, and ARID1A alterations were detected in 66%, 29%, 27%, 24%, and 22% of all patients, resp…
RT @VivekSubbiah: 3/6 Patients' tumors or circulating tumor DNA were analyzed by NGS. The median progression-free survival was 4.2 months,…
RT @VivekSubbiah: 6/6 Implications: Patients with platinum-refractory mBC derive clinical benefit from participating in early-phase clinica…
RT @oncologician: 📣Excellent thread on Precision oncology in Urothelial ca 🎯🧬 https://t.co/WT6fb0tpnH
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @oncologician: 📣Excellent thread on Precision oncology in Urothelial ca 🎯🧬
RT @VivekSubbiah: 6/6 Implications: Patients with platinum-refractory mBC derive clinical benefit from participating in early-phase clinica…
📣Excellent thread on Precision oncology in Urothelial ca 🎯🧬
RT @VivekSubbiah: 4/6 TP53, ERBB2, PI3KCA, FGFR3, and ARID1A alterations were detected in 66%, 29%, 27%, 24%, and 22% of all patients, resp…
RT @VivekSubbiah: 3/6 Patients' tumors or circulating tumor DNA were analyzed by NGS. The median progression-free survival was 4.2 months,…
RT @VivekSubbiah: 2/6 Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies @OncoAl…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published a…
RT @VivekSubbiah: 6/6 Implications: Patients with platinum-refractory mBC derive clinical benefit from participating in early-phase clinica…
6/6 Implications: Patients with platinum-refractory mBC derive clinical benefit from participating in early-phase clinical trials and their survival outcomes correlate with the genetic profile of the tumor. #bcsm #GU21 @MCR_AACR https://t.co/ING3h1JEIH ht
3/6 Patients' tumors or circulating tumor DNA were analyzed by NGS. The median progression-free survival was 4.2 months, the median overall survival was 9.6 months, and the overall response rate was 17.5%. #GU21 @MCR_AACR @oalhalabimd #bcsm https://t.co/I
2/6 Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies @OncoAlert @MCR_AACR @oalhalabimd . #bcsm https://t.co/ING3h1JEIH
1/6⭐️🚨Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published as Rapid impact paper @oalhalabimd et al @MCR_AACR @AACR @CancerMedMDA #GU21 @ASCO @OncoAlert #bcsm https://t.co/ING3h1JEIH https:/
RT @VivekSubbiah: 🚨🥁 Just in time for #GU21 @ASCO 👉 Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts…
RT @VivekSubbiah: 🚨🥁 Just in time for #GU21 @ASCO 👉 Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts…
RT @VivekSubbiah: 🚨🥁 Just in time for #GU21 @ASCO 👉 Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts…
RT @VivekSubbiah: 🚨🥁 Just in time for #GU21 @ASCO 👉 Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts…
RT @VivekSubbiah: 🚨🥁 Just in time for #GU21 @ASCO 👉 Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts…
RT @VivekSubbiah: 🚨🥁 Just in time for #GU21 @ASCO 👉 Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts…
🚨🥁 Just in time for #GU21 @ASCO 👉 Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published as Rapid impact paper @oalhalabimd et al @MCR_AACR @AACR @CancerMedMDA #bcsm https://t.co/ING3h1JEIH https:
RT @oalhalabimd: For 2020, I was very fortunate for the sponsorship, mentorship and guidance by many great people but @VivekSubbiah stands…
RT @VivekSubbiah: 23. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes @A…
RT @oalhalabimd: For 2020, I was very fortunate for the sponsorship, mentorship and guidance by many great people but @VivekSubbiah stands…
For 2020, I was very fortunate for the sponsorship, mentorship and guidance by many great people but @VivekSubbiah stands out as a brilliant dynamo ⚡️ that charges others with enormous energy! + a very caring human being!
23. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes @AACR @oalhalabimd @MCR_AACR https://t.co/6OulRy5lam
RT @MCR_AACR: Patients with metastatic #BladderCarcinoma and a targetable alteration may derive clinical benefit from participating in earl…
Patients with metastatic #BladderCarcinoma and a targetable alteration may derive clinical benefit from participating in early phase trials involving targeted therapy, but patients with TP53-alt need innovative therapies. @MDAndersonNews https://t.co/MpDw
RT @oalhalabimd: 1/🌟 Excited to share our brief paper with @OncHahn @PavlosMsaouel @JasonRoszik and @MDAndersonNews team, looking at patien…
RT @oalhalabimd: 1/🌟 Excited to share our brief paper with @OncHahn @PavlosMsaouel @JasonRoszik and @MDAndersonNews team, looking at patien…
RT @VivekSubbiah: 🚨⭐️Such a delight to work with the amazing team @oalhalabimd @OncHahn @PavlosMsaouel @CancerMedMDA on Molecular profiling…
RT @VivekSubbiah: 🚨⭐️Such a delight to work with the amazing team @oalhalabimd @OncHahn @PavlosMsaouel @CancerMedMDA on Molecular profiling…
RT @VivekSubbiah: 🚨⭐️Such a delight to work with the amazing team @oalhalabimd @OncHahn @PavlosMsaouel @CancerMedMDA on Molecular profiling…
RT @VivekSubbiah: 🚨⭐️Such a delight to work with the amazing team @oalhalabimd @OncHahn @PavlosMsaouel @CancerMedMDA on Molecular profiling…
RT @oalhalabimd: 1/🌟 Excited to share our brief paper with @OncHahn @PavlosMsaouel @JasonRoszik and @MDAndersonNews team, looking at patien…
Nice #cancerresearch for #metastatic #bladdercancer. Authors found that patients w/mBC derive clinical benefit from participating in phase 1 #clinicaltrials but many can't enroll due to strict eligibility criteria. Criteria needs to be expanded. Also genom
RT @oalhalabimd: 1/🌟 Excited to share our brief paper with @OncHahn @PavlosMsaouel @JasonRoszik and @MDAndersonNews team, looking at patien…
RT @oalhalabimd: 1/🌟 Excited to share our brief paper with @OncHahn @PavlosMsaouel @JasonRoszik and @MDAndersonNews team, looking at patien…
RT @oalhalabimd: 1/🌟 Excited to share our brief paper with @OncHahn @PavlosMsaouel @JasonRoszik and @MDAndersonNews team, looking at patien…
RT @VivekSubbiah: 🚨⭐️Such a delight to work with the amazing team @oalhalabimd @OncHahn @PavlosMsaouel @CancerMedMDA on Molecular profiling…
🚨⭐️Such a delight to work with the amazing team @oalhalabimd @OncHahn @PavlosMsaouel @CancerMedMDA on Molecular profiling of met. bladder cancer patients on #Immunotherapy & targeted therapy trials @MDAndersonNews cc' @montypal @neerajaiims @PGrivasMDP
RT @oalhalabimd: 1/🌟 Excited to share our brief paper with @OncHahn @PavlosMsaouel @JasonRoszik and @MDAndersonNews team, looking at patien…
RT @oalhalabimd: 1/🌟 Excited to share our brief paper with @OncHahn @PavlosMsaouel @JasonRoszik and @MDAndersonNews team, looking at patien…
1/🌟 Excited to share our brief paper with @OncHahn @PavlosMsaouel @JasonRoszik and @MDAndersonNews team, looking at patients with #bladdercancer that enrolled on #targeted therapy and next-gen #Immunotherapy #phase1 trials. Mentored by @VivekSubbiah https